Immunic, Inc. Operating Cash Flow
Immunic, Inc. (IMUX) reported Operating Cash Flow of -$48.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Immunic, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.00M.
- Immunic, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$17.30M.
- Immunic, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$19.28M.
- Immunic, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$20.14M.
- Immunic, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$85.81M.
- Immunic, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$84.77M.
- Immunic, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$70.83M.
- Immunic, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$65.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$31.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$48.30M 10-Q · filed 2026-08-11 | -$67.58M derived: sum of 3 quarters · filed 2026-08-11 | -$87.72M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$17.30M 10-Q · filed 2026-05-13 | -$36.58M derived: sum of 2 quarters · filed 2026-05-13 | -$56.72M derived: sum of 3 quarters · filed 2026-05-13 | -$81.33M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$19.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$39.42M derived: sum of 2 quarters · filed 2026-02-26 | -$64.03M derived: sum of 3 quarters · filed 2026-08-11 | -$85.81M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$20.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$44.75M derived: sum of 2 quarters · filed 2026-08-11 | -$66.53M 10-Q · filed 2025-11-13 | -$89.49M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$24.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$46.38M 10-Q · filed 2026-08-11 | -$69.35M derived: sum of 3 quarters · filed 2026-08-11 | -$90.14M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$21.78M 10-Q · filed 2026-05-13 | -$44.74M derived: sum of 2 quarters · filed 2026-05-13 | -$65.53M derived: sum of 3 quarters · filed 2026-05-13 | -$82.57M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$22.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$43.76M derived: sum of 2 quarters · filed 2026-02-26 | -$60.80M derived: sum of 3 quarters · filed 2026-02-26 | -$84.77M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$20.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$37.83M derived: sum of 2 quarters · filed 2025-11-13 | -$61.80M 10-Q · filed 2025-11-13 | -$75.83M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$17.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$41.01M 10-Q · filed 2025-08-07 | -$41.00M 10-Q · filed 2024-08-08 | -$55.03M derived: sum of 3 quarters · filed 2025-08-07 | -$72.35M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$23.97M 10-Q · filed 2025-05-15 | -$38.00M derived: sum of 2 quarters · filed 2025-05-15 | -$55.31M derived: sum of 3 quarters · filed 2025-05-15 | -$75.28M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$14.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$31.34M derived: sum of 2 quarters · filed 2025-03-31 | -$51.31M derived: sum of 3 quarters · filed 2025-03-31 | -$70.83M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$17.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$37.29M derived: sum of 2 quarters · filed 2024-11-07 | -$56.80M 10-Q · filed 2024-11-07 | -$71.91M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$19.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$39.49M 10-Q · filed 2024-08-08 | -$54.59M derived: sum of 3 quarters · filed 2024-08-08 | -$68.19M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$19.51M 10-Q · filed 2024-05-08 | -$34.62M derived: sum of 2 quarters · filed 2024-05-08 | -$48.21M derived: sum of 3 quarters · filed 2024-05-08 | -$63.98M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | -$15.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$28.70M derived: sum of 2 quarters · filed 2024-02-22 | -$44.46M derived: sum of 3 quarters · filed 2024-02-22 | -$65.14M 10-K · filed 2024-02-22 | ||||
| 2022-09-30 | -$13.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$29.36M derived: sum of 2 quarters · filed 2023-11-14 | -$50.04M 10-Q · filed 2023-11-14 | -$73.72M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$15.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$36.44M 10-Q · filed 2023-08-03 | -$60.13M derived: sum of 3 quarters · filed 2023-08-03 | -$77.72M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$20.68M 10-Q · filed 2023-05-11 | -$44.36M derived: sum of 2 quarters · filed 2023-05-11 | -$61.96M derived: sum of 3 quarters · filed 2023-05-11 | -$90.97M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$23.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$41.28M derived: sum of 2 quarters · filed 2023-02-23 | -$70.28M derived: sum of 3 quarters · filed 2023-02-23 | -$83.23M 10-K · filed 2023-02-23 | ||||
| 2021-09-30 | -$17.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$46.60M derived: sum of 2 quarters · filed 2022-11-03 | -$59.55M 10-Q · filed 2022-11-03 | -$73.52M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$41.95M 10-Q · filed 2022-08-04 | -$55.92M derived: sum of 3 quarters · filed 2022-08-04 | -$67.82M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$12.95M 10-Q · filed 2022-05-10 | -$26.91M derived: sum of 2 quarters · filed 2022-05-10 | -$38.82M derived: sum of 3 quarters · filed 2022-05-10 | -$48.04M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$25.87M derived: sum of 2 quarters · filed 2022-02-24 | -$35.09M derived: sum of 3 quarters · filed 2022-02-24 | -$46.12M 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | -$11.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$21.13M derived: sum of 2 quarters · filed 2021-11-04 | -$32.16M 10-Q · filed 2021-11-04 | -$38.43M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$9.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$20.26M 10-Q · filed 2021-08-06 | -$26.52M derived: sum of 3 quarters · filed 2021-08-06 | -$32.50M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | -$11.03M 10-Q · filed 2021-05-06 | -$17.29M derived: sum of 2 quarters · filed 2021-05-06 | -$23.27M derived: sum of 3 quarters · filed 2021-05-06 | -$34.26M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | -$6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$12.24M derived: sum of 2 quarters · filed 2021-02-26 | -$23.23M derived: sum of 3 quarters · filed 2021-02-26 | -$28.55M 10-K · filed 2021-02-26 | ||||
| 2019-09-30 | -$5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$16.96M derived: sum of 2 quarters · filed 2020-11-06 | -$22.28M 10-Q · filed 2020-11-06 | -$25.73M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | -$10.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | -$16.30M 10-Q · filed 2020-08-03 | -$19.75M derived: sum of 3 quarters · filed 2020-08-03 | |||||
| 2019-03-31 | -$5.32M 10-Q · filed 2020-05-08 | -$3.74M 10-Q · filed 2019-04-10 | -$8.76M derived: sum of 2 quarters · filed 2020-05-08 | |||||
| 2018-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$9.74M 10-K · filed 2020-03-16 | -$43.16M 10-K · filed 2019-03-04 | |||||
| 2018-09-30 | -$6.29M 10-Q · filed 2019-11-07 | -$38.51M 10-Q · filed 2018-11-08 | ||||||
| 2018-03-31 | -$13.07M 10-Q · filed 2019-04-10 | -$22.99M derived: sum of 2 quarters · filed 2019-04-10 | ||||||
| 2017-12-31 | -$9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-04 | -$40.40M 10-K · filed 2019-03-04 | ||||||
| 2017-09-30 | -$30.48M 10-Q · filed 2018-11-08 | |||||||
| 2016-12-31 | -$35.77M 10-K · filed 2019-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |